The firm brings unique experience to tracking, assessing and explaining regulatory and reimbursement policy that affect the biopharmaceutical industry. The company’s goal is to advance mutual understanding among policymakers, business executives and the investment community, in the belief that a deeper understanding of policy leads to better business, and a deeper understanding of business leads to better policy.
Member Sign In:
- Sen. Warren’s NIH Royalty Bill Shows Risk of 21st Century Cures Process For Biopharma – But Also That Risk Is Very Limited Jan. 23, 2015
- FDA Pharmacy Compounding Committee Will Review List of Acceptable Bulk Substances In February Jan. 23, 2015
- Astellas Antifungal Isavuconazole Clears Committee; Another Case Study In Favorable FDA Climate For Infectious Diseases Jan. 22, 2015
See More Research Notes